Lodestar Minerals (ASX: LSR) has intersected visible copper sulphides in its maiden drill hole at the Three Saints Project in Chile, with multiple zones of chalcopyrite identified, highlighting the project’s potential within a highly prospective mineralised region. The mineralisation remains open at depth, with follow-up drilling is already planned to test extensions of the system.

⛏️ LSR’s maiden drill hole has identified visible copper sulphides intersections, with chalcopyrite, magnetite, pyrite and molybdenite identified across multiple intervals from, with mineralisation remaining open at depth.
📈 This mineralisation strengthens with depth, with visual observations indicating an increase in concentration further down the hole, supporting the geological model for a copper system in the region.
🔬 Assays and follow-up drilling is planned, with the drill core currently being transported for detailed laboratory analysis, while a second step-out diamond drill hole is set to commence, targeting extensions of the mineralised system.

Lodestar Minerals Executive Director Coraline Blaud commented:
“The observation of chalcopyrite and magnetite in our maiden drill hole at Three Saints is a very encouraging indication that this first hole has intersected a potential economic system. The alteration and sulphide assemblages identified are consistent with IOCG-style (Iron Oxide Copper Gold) mineralisation recognised elsewhere in this highly prospective belt.”

InteliCare Holdings (ASX:ICR) has secured a major aged care technology agreement with MECWA, signing a five-year Master Subscription Agreement to deploy its digital care platform across 22 residential aged care facilities in Victoria. The deal, valued around $8.8 million on full deployment, represents InteliCare’s largest contract to date and highlights growing demand for digitally enabled care solutions in the aged care sector.

🏥 Major aged care deployment secured, with InteliCare signing a five-year Master Subscription Agreement with Mecwacare to deploy its analytics, IoT and integrated nurse call platform across 22 residential aged care facilities, supporting around 1,600 residents.
🩺 The contract, valued at about $8.8 million on full deployment, represents the largest deployment in InteliCare’s history and highlights the increased adoption of digital monitoring and data-driven care solutions within aged care providers.
💻 This digital transformation partnership with Mecwacare in implementing InteliCare’s platform is part of a broader initiative to improve resident outcomes, enhance workforce efficiency and support long-term operational sustainability across its aged care network.

InteliCare Holdings Non-Executive Director Tim Chapman commented:
“This agreement represents a defining milestone for InteliCare. Securing a five-year agreement with Mecwacare validates the scalability of our platform and confirms that data-driven, real-time intelligence is becoming foundational to the future of aged care. This agreement positions InteliCare as a strategic technology partner for sector wide transformation and we look forward to announcing further partnerships in due course.”

dorsaVi (ASX: DVL) is evaluating Resistive Random Access Memory (RRAM) test chips, marking the first step in its development program toward an advanced memory platform. The technology is designed to support growing AI demand in robotics, drones and autonomous systems while enabling next-generation in-memory computing architectures.

💾 RRAM development program underway, with dorsaVi receiving initial test silicon and beginning early-stage device characterisation, forming the foundation of its pathway toward a scalable RRAM platform.
⚡ The AI memory architecture is planned to enable higher memory density, faster data access speeds and lower power consumption compared with legacy memory processes.
🤖 dorsaVi is positioned for emerging AI and robotics demand, as robotics, drones and autonomous systems increasingly require compact, high-performance memory capable of processing sensor data and running onboard AI under strict power and size constraints.

dorsaVi Chief Executive Officer Mathew Regan commented:
“Our RRAM-based in-memory and neuromorphic computing platform is being developed to reduce data movement and enable ultra-low-power, low-latency intelligence where efficiency is critical. We believe our technology roadmap is aligned with these structural industry trends.”

National Stock Exchange of Australia is evolving under the leadership of Canadian Securities Exchange, focusing on early-stage and growth companies. The acquisition by CSE positions NSX as a platform for cross-border listings, providing retail and institutional investors in Australia and Canada with improved access to capital, liquidity, and trading opportunities. Ahead of appearing at Stocks on Location in Sydney - Max Cunningham, Managing Director and CEO of NSX, joins to discuss how the exchange is being reshaped and the opportunities this creates for founders and investors.

🇨🇦 CSE acquisition and growth strategy
🤝 Exchange structure and investor benefits
⚙️ Leadership and operational priorities

Bass Oil (ASX:BAS) is an Australian oil and gas producer with assets in the Cooper Basin and Indonesia, holding 100% ownership of the Worrior and Padulla oil fields and progressing the Vanessa gas field acquisition. The Company recently reported steady oil production and revenue while advancing plans to bring its first gas production online into the tight East Coast Gas Market. Bass has also secured A$3.5 million in South Australian Government funding to accelerate development of the Kiwi gas field. With the Company’s share price rising more than 100% over the past six months, Managing Director Tino Guglielmo joins The Stock Network’s Lel Smits to discuss production, gas development and upcoming catalysts.

⛽ Positioning for East Coast gas demand
📈 Share price momentum and upcoming catalysts

Adherium (ASX: ADR) is showing strong commercial momentum with its Hailie® Smartinhaler® and cloud-based platform, as Remote Patient Monitoring (RPM) revenue, device shipments, and patient activations continue to climb. This growth reflects the scalability of Adherium’s digital respiratory care platform.

🩺 RPM revenue is growing quickly, with its February 2026 figure up 51% on that for December 2025 to February 2026; combined January/February 2026 RPM revenue has already surpassed that for the Dec-25 quarter.
🚀 Adherium’s cumulative RPM shipments were up 43% and activations up 53% between end-December 2025 and end-February 2026, underscoring the strength of Adherium’s commercial model.
🌎 Adherium’s patient pipeline continues to expand, with access to roughly 48,000 insurance verified asthma patients via its call centre and partners including Allergy Partners, supporting its target of 10,000 RPM patients by the end of 2026.

Adherium Chief Executive Officer Dawn Bitz commented:
“ Through our collaboration with Allergy Partners, we`ve built a major platform for growth - clinicians want patients to have our technology and patients are benefitting significantly from improved respiratory outcomes. With the benefit of these initiatives and reimbursement tailwinds, we have strong confidence in delivering our previously announced target of 10,000 RPM patients by the end of 2026.”

Emmerson Resources (ASX:ERM) is acquiring Pan African Resources in a transaction valued at approximately A$311 million. The deal provides shareholders with an immediate value realisation event and continued exposure to a cash-generating gold producer.

⛏️ This acquisition adds scale and production capacity, giving ERM access to a broader portfolio of gold assets and a more resilient revenue base.
🏭 Shareholders gain exposure to steady cash generating operations, supporting investment in future projects and accelerating development across key assets.
🌏 The merger strengthens Emmerson Resources’ strategic presence in the Tennant Creek region, and creates a platform for potential growth and value creation in the broader gold sector.

Emmerson Resources Chairman Mark Connelly commented:
“The transaction delivers our shareholders with an immediate value realisation event at an attractive premium, whilst providing exposure to a larger, more diversified and well-capitalised gold producer with a broad portfolio and a strengthened platform for long-term value creation.”

Dimerix (ASX:DXB) has successfully concluded the ACTION3 Phase 3 trial of DMX-200 in focal segmental glomerulosclerosis (FSGS), completing recruitment beyond the targeted 286 adults. The study is on track to deliver full 2-year data in March 2028. The milestone strengthens the statistical power of the trial and positions Dimerix for future regulatory submission and commercialisation.

💉 ACTION3 Phase 3 has now dosed 333 adult patients, exceeding the original target due to patients already in screening being allowed to progress. This strengthens the study’s ability to detect treatment effects.
⏳ A 2-year study, evaluating DMX-200 remains on track for completion in March 2028, generating robust data on proteinuria reduction and kidney function.
🚀 Achieving this milestone de-risks the study, positioning Dimerix to advance toward regulatory submission, potential approval, and commercialisation while maintaining focus on licensing opportunities.

Dimerix Managing Director Nina Webster commented:
“I am delighted with the achievement of such a significant milestone in the Company’s clinical development of DMX-200 in FSGS patients. Dimerix and our current commercial partners are well positioned to continue to advance toward regulatory submission and potential approval and commercialisation of DMX-200. We are sincerely grateful to the patients and their families for their vital contribution to this important program."